

Clinical and Translational Research Committee (CTRC)

Supplementary Terms of Reference

- 1 Remit:** to be responsible to the Scientific Executive Board (SEB) for overseeing the development of a comprehensive portfolio of translational research and clinical trials for Cancer Research UK by:
- (i) advising the SEB on how the charity can best invest its resources to improve national capacity and capability to undertake clinical trials and translational research for the benefit of cancer patients
 - (ii) promoting an awareness and understanding within the charity of how strategic, tactical and other funding decisions impact on the charity's capability to contribute to the creation of an important portfolio of translational research and clinical trials
 - (iii) identifying opportunities and potential partnerships with other research funders, the wider academic and industrial community to deliver the strategic goals of the charity for translational research and clinical trials
 - (iv) recommending the nature, configuration and level of funding required to deliver the charity's strategic goals for translational research and clinical trials
 - (v) funding the schemes and infrastructure required to develop and evaluate novel preventative, diagnostic, therapeutic agents, strategies and interventions

In fulfilment of this the CTRC will work with:

- The NCRI Board, NCRN, and OnCoreUK to identify areas of mutual interest and develop a coherent programme of work which fulfils the charity's strategic aims.
- The Discovery Committee, New Agents Committee, Biomarkers and Imaging Discovery and Development Committee (formerly Translational Research in Clinical Trials Committee), Clinical Trials Advisory and Awards Committee, Discovery Co-ordinating Committee, and Cancer Imaging Review Group.
- Other committees, panels or working groups established by the CTRC in fulfilment of its remit.

2 Additional Terms:

- 2.1 To recommend terms of reference for (including memberships and mode of operation) and then establish necessary funding Sub-Committees. To delegate to them the authority to take decisions and make awards within their budgets and areas of responsibility.

- 2.2 To establish whatever funding schemes it considers necessary to meet the scientific strategic objectives for translational research and clinical trials; to monitor these, and to close schemes which it considers no longer appropriate.
- 2.3 To receive the minutes (or other record) of the funding Sub-Committees and overview their decisions particularly in the light of strategic implications or major impact on translational research and clinical trials infrastructure.
- 2.4 To ensure that Cancer Research UK research groups have appropriate access to translational research and clinical trial infrastructure and to prioritise and resolve issues of access when necessary.
- 2.5 To communicate information on translational research and clinical trial activities by the most appropriate mechanisms to the Cancer Research UK research community and to stimulate interaction and involvement.
- 2.6 To consider the charity's interaction with other bodies, both national and international, and to provide to the SEB information on the value of these partnerships in promoting the scientific research strategy for translational research and clinical trials.
- 2.7 To receive reports from the relevant NCRI sub-boards and committees and meet with representatives of UKCRN, NCRN, OnCore UK, NIHR, as well as any future relevant government-sponsored bodies to discuss issues of common interest and evolve functional partnerships.
- 2.8 To ensure that processes are in place for the (commercial) development of research outputs including an appropriate interface with Cancer Research Technology.

3 Membership:

- 3.1 The membership will be:

Executive Director of Clinical and Translation Operations and Funding Directorate
 Director of Drug Development
 Director of Clinical Trials
 Director of CR-UK Centres
 Director of Business Management, Cancer Research Technology
 Chief Clinician
 Between 5 and 10 clinicians and translational scientists
 Chairs of Funding Sub Committees and Oversight Committees

- 3.2 The following may attend in an ex-officio capacity:
 Director of NCRN

- 3.3 The following may attend by invitation for specific discussions or meetings:
 Director of OnCore UK
 Director of NCRI
 Director of NIHR Clinical Research Co-ordinating Centre
 Chairman of NCRI Translational Clinical Studies Group

- 4 Meetings:** the Committee will meet three times a year.